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Abstract  Original Research Article 
 
The aim of this study is to determine the impact caused by direct compression on the crystalline state of two 
prototypes of Rupatadine fumarate 10 mg tablets. The tablets were manufactured through direct compression. Five 
grams powdered tablets samples were taken randomly for analysis through DSC, TGA and XRD. The results were 
analyzed by making a comparison between their crystalline characterization and the one shown by the active 
pharmaceutical ingredient, excipients, the placebo and the powdered formula before compression. The active 
pharmaceutical ingredient showed a melting point at 201.38 °C, which decreased 2 – 3 °C in the tablets’ thermograms. 
Placebos presented an endotherm at 228 °C characteristic of amorphous lactose’s melting point. The only thermal 
change presented between the tablets and the other samples is the crystallization of amorphous lactose around 172 – 
176 °C. X-ray diffractograms showed an increased intensity for the peaks of α - lactose monohydrate after 
compression and no changes regarding the active pharmaceutical ingredient. The comparison done between the 
analyses, confirmed that compression didn’t impact the crystalline state of Rupatadine fumarate. However mechanical 
treatment and the influence of the excipients caused the fusion peak to shift towards lower temperatures. Lactose’s 
crystal lattice suffered the greatest impact caused by compression, which generated the crystallization of the 
amorphous region present in that raw material. Nevertheless, such modification doesn’t alter the prototypes’ aptitude 
for being developed into a final solid pharmaceutical form and it is not a situation that affects the product’s quality. 
Keywords: Compression impact, Crystallization, Direct compression, Polymorphism, Rupatadine fumarate, Tablet. 
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INTRODUCTION 
Tablets are the most common pharmaceutical 
form designed for treatment. Patients prefer taking 
tablets because they’re easy to take and handle. 
Additionally, they’re considered more suitable for large 
scale production and are more cost effective [1, 2]. 
 
Although direct compression is the most 
economical technique for tablet manufacturing, the 
method is affected by the attributes of raw materials. 
Some of their properties have been found to affect the 
parameters of the compressed solid product; like the 
crystallinity, moisture content, tensile strength, particle 
size, surface area and density. Therefore, excipients’ 
properties and their impact on the performance of the 
solid formulation must be studied [3-5].  
 
However, compression can induce 
physicochemical changes in bulk powders of the 
excipients and in the API as well. From the mentioned 
properties of raw materials, the most important one is 
the crystallinity, which is directly involved in the 
compactibility, tablet hardness, lamination, 
disintegration time and dissolution rate. The previous is 
really important because tablets should be able to 
withstand the rigors of the manufacturing processes and 
in the distribution system as well [1, 5].  
 
Despite the reports on mechanical studies of 
tableting, there are few investigations describing the 
changes in physicochemical properties caused by the 
compression process. Specifically, those regarding the 
crystalline state of the API and the matrix of the 
formulation [5]. 
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Several manufacture operations within the 
compression process, such as milling, mechanical 
dispersive techniques, high shear mixing and 
granulation; use mechanical energy for the physical 
manipulation of the formulation mixtures. This can 
destabilize crystalline and amorphous phases leading to 
phase transitions [5-7]. 
 
However, compression causes the greatest 
changes in terms of the crystal lattice. During the 
compression process, solid particles rearrange and the 
massive force is able to cause their deformation. This is 
similar to the formation of large crystals or aggregates 
when melting. Additionally, the compression reduces 
the distance between the molecules and their 
interparticulate porosity, causing particles to fragment 
and form a compact [6].  
 
Precisely, the distance reduction between the 
molecules is an endothermic process that requires a 
considerable amount of energy in order to form a 
compact with a high surface area. On the other hand, 
particle bonding during compression is an exothermic 
process that can be explained through different 
mechanisms such as solid bridges, distance attraction 
forces and mechanical interlocking [1].  
 
The components of the bed powder can suffer 
various physical transformations when subject to 
compression, such as Amorphous – Crystalline, 
Anhydrate – Hydrate and Polymorphic transitions. 
Amorphous and crystalline forms of the same molecule 
can show a different behavior during the manufacturing 
process. It is important to mention that many 
pharmaceutical excipients exist in an amorphous state, 
which seems to improve the handling and offers better 
mechanical properties, especially regarding aqueous 
solubility [5, 6, 8].  
 
Polymorphism constitutes a factor that can’t be 
ignored since the different arrangements in the crystal 
lattice of the raw materials, cause solids to have 
different physicochemical properties that can 
potentially influence the ones of the drug product and 
therefore, the therapeutic effect. Thus, regulatory 
entities like the FDA have highlighted their concern 
about the establishment and declaration of the API’s 
and excipients’ polymorphic transitions when filling 
dossiers [9-11]. 
 
But also, due to the mechanical stress induced 
by the compression process, nucleation sites can be 
formed leading to physical or chemical reactions, 
decreasing the physicochemical stability of the tablets. 
Even though only a small fraction of a formulation may 
undergo a physical change, it can represent a risk for 
the quality of the final product. The identification, 
monitorization and characterization of such transitions 
due to compression are commonly done through the 
combination of different analytical techniques such as 
DSC, TGA, XRD, NMR, and Raman Spectroscopy [7, 
9, 12].  
 
This investigation focuses on the 
determination of the impact caused by direct 
compression on the crystalline state of two prototypes 
of Rupatadine fumarate 10 mg tablets, by making a 
comparison between their crystalline characterization 
and the one shown by the API, excipients, the placebos 
and the powdered formulas before the compression.  
 
The mentioned characterization and analysis 
were done through DSC, TGA and XRD. 
MATERIALS AND METHODS 
Materials 
Table-1: Materials used for the research and formulation prototypes. 
Raw materia Manufacturer Formula 1 Formula 2 
Rupatadine Fumarate Enaltec laboratories India, batch No. EL-03/L095/16025   
Lactose monohydrate DFE Pharma, batch No. 1010KX2   
Microcrystalline cellulose DFE Pharma, batch No. 100202   
Sodium croscarmellose JRS Pharma, batch No. 7111512407   
Magnesium stearate Helianthus, batch No. MGSV150475   
PVP K-30 Ashland, batch No. 0001855552 X  
 
Methods 
Manufacturing 
The tablets were manufactured through direct 
compression using an Adept tablet press machine, 
model D – D – 27 with 1/8 inch punches. For each 
formulation prototype, the hardness of the tablets was 
maintained between 5 – 6.5 kp. The target weight per 
tablet was 120 mg ± 5 %. 
 
 
 
 
Crystalline characterization 
The analyses done to the tablets were 
compared to the ones performed previously to the 
placebos, the powdered formulas and the API. Five 
grams of powdered tablet samples of each formula were 
taken randomly and transferred to the test site under 
controlled conditions of temperature, light and 
humidity. The conditions and specifications of the 
equipment used were the following: 
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Differential Scanning Calorimetry 
Equipment: DSC TA Instruments model Q200. 
Conditions: 
 Aluminum capsule. 
 100% Nitrogen Atmosphere 10 psi. 
 Flow rate: 40 mL / minute. 
 Heating series: isotherm at 20 °C for 5 minutes, 
then increase 10 °C / minute. 
 Temperature range: 20 °C to 250 °C. 
 Sensitivity Instrument and Recorder: Sensitivity 
0.1 uW. 
 Temperature precision: ± 0.05 °C. 
 Temperature accuracy: ± 1 °C. 
 Calorimetric precision: ± 0.1 %. 
 Calorimetric reproducibility: ± 0.1 %. 
 Weight: 4 to 5 mg sample. 
 Calibration with Indium and distilled water.  
 Three replicas. 
 
Thermogravimetric Analysis 
Equipment: TGA TA Instruments model Q500. 
Conditions: 
 100% Nitrogen 10 psi Atmosphere. 
 Volume flow: 40 mL / minute. 
 Heating rate: 10 °C / minute. 
 Temperature range: 20 °C to 1000 °C. 
 Weight: 4 to 5 mg sample. 
 Sensitivity: 0.1 ug. 
 Isothermal temperatura accuracy: ± 0.1 %. 
 Isothermal temperatura precision ± 0.1 %. 
 Three replicas. 
 
X-ray Diffraction  
Equipment: Diffractometer: PANalytical Empyrean. 
Conditions: 
 Temperature: Room temperatura 25 °C. 
 Nickel filter. 
 Copper anode source Kα [λ 1, 54 A°]. 
 Polymethacrylate sample holder. 
 Continuous analysis at 0.1° per second in the range 
of 3° to 40 ° 2θ. 
 Gas detector with photodiodes. 
 Weight: 10 to 15 mg sample. 
 Three replicas.  
 
RESULTS 
Differential Scanning Calorimetry  
 
 
Fig-1: DSC analysis of prototype’s 1 samples 
 
 
Fig-2: DSC analysis of prototype’s 2 samples 
 
 
 
Luis Castillo Henríquez et al., Sch Acad J Pharm, Nov, 2019; 8(11): 465-472 
© 2019 Scholars Academic Journal of Pharmacy | Published by SAS Publishers, India                                                                                          468 
 
 
Figures 1 and 2 illustrate a thermal event for 
the API at 201.38 °C. In the two prototypes it is 
possible to observe that the placebo, powdered formula 
and tablet show two characteristic endothermic events; 
one around 142 – 148 °C and the other one near 214 – 
218 °C.  
 
Moreover, it can be seen that only the placebos 
show an endothermic event around 228 °C, which is 
characteristic of an amorphous material.  However, the 
only thermal change presented between the tablets and 
the other samples, is an exothermic peak that appears 
around 172 – 176 °C. 
Thermogravimetric Analysis  
 
Fig-3: TGA of prototype’s 1 samples 
 
 
Fig-4: TGA of prototype’s 2 samples 
 
Figures 3 and 4 show no mass decrease from 0 
– 150 °C for the API. However, there’s evidence of a 20 
% of mass loss between 205 – 208 °C. The three 
samples; placebo, powdered formula and tablets of the 
two prototypes, exhibit a very similar behavior for this 
analysis. Their thermograms show an initial mass 
reduction between 140 - 210 °C. A second mass loss is 
presented from 210 - 280 °C.   
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X-Ray Diffraction  
 
Fig-5: XRD analysis of prototype’s 1 samples 
 
 
Fig-6: XRD analysis of prototype’s 2 samples 
 
Figures 5 and 6 exhibit a classic crystalline 
pattern. Before compression, the powdered formulas 
show the API’s six characteristic peaks, which can be 
identified in the two prototypes tablets as well. The 
mentioned peaks are: 13.6, 17.0, 20.2, 21.3, 23.6 and 
25.8 2θ [13,14].  
 
The placebo and powdered formulas show 
other main peaks that are not related to the API at 12.4, 
16.4, 19.8, 20.7 and 22.7 2θ. Similar diffraction patterns 
were observed for the tablet formulations. However, the 
diffractograms of each tablet prototype differ from their 
corresponding placebo and powdered formula in the 
intensity of the peaks at 12.4, 16.4 and 19.8 2θ.  
 
DISCUSSION 
Additional to the execution of compatibility 
studies, it is also important to analyze the impact 
generated by the manufacturing processes on the 
properties of raw materials and the finished product 
[15].  
 
In a previous investigation, we characterized 
the thermal behavior of the API, placebos and the 
powdered formula, where we were able to conclude that 
no interaction or incompatibility between the raw 
materials was presented. Briefly, the thermal event 
presented by the API at 201.83 °C in the DSC analysis 
is its melting point, followed by its decomposition as 
confirmed by the mass loss in the TGA thermogram 
[15].  
 
The endothermic event showed by all samples 
around 142 – 148 °C in the DSC analysis, including 
tablets, is due to the dehydration of lactose 
monohydrate, which matches their first mass loss 
presented in the TGA thermograms [15-19]. 
 
Also, earlier work from our laboratory has 
demonstrated the existence of only one crystalline form 
for Rupatadine fumarate, which is form A. Thus, a 
polymorphic transition is not contemplated as a possible 
effect on the crystalline state of the API due to 
compression. The diffractograms for the placebos, 
powdered formulas and tablets in figures 5 and 6 show 
that the characteristic peaks of the API are still present 
but are less intense because its presence in the 
formulations is reduced compared to its individual 
analysis [13].  
 
Although it seems that Rupatadine fumarate 
didn’t change its solid state nature at all, it is possible to 
notice that its melting point decreased 2 – 3 °C in the 
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tablets samples. This is because the excipients can 
lower this physicochemical property of pure drugs 
during compression, by causing a surface fusion before 
its normal melting [1,2].  
 
However, figures 1 and 2 present an 
exothermic event for the tablets which is related to 
compression, at 172 – 176 °C. Nevertheless, the new 
peak doesn’t match to a mass loss in the TGA presented 
in figures 3 and 4, so a chemical reaction such as 
decomposition is discarded. In DSC analysis, an 
exothermic peak can also be explained by a change in 
the crystalline structure of the sample [15]. 
 
Taking into consideration that the API didn’t 
suffer any physical or chemical change and a new 
exothermic peak appeared in the tablets’ DSC analysis, 
it is important to analyze which raw materials could 
have suffered a change in their crystal structure, 
specially the diluents because they are present in a 
greater proportion.  
 
Regarding microcrystalline cellulose, we chose 
polymorph I which is widely used as a pharmaceutical 
aid for compression because of its adequate 
compactability and compressibility properties. The 
revised literature states that neither polymorphic form I 
nor II are affected by compression. Therefore, a change 
in the crystal lattice of this excipient is discarded as 
well [4, 20]. 
 
On the other hand, lactose monohydrate’s 
thermal behavior has some particular aspects that are 
worth analyzing. This is because there are three other 
polymorphic forms involved: Stable anhydrous α - 
lactose, unstable anhydrous α - lactose and anhydrous β 
- lactose. In addition, amorphous lactose can also be 
presented [8, 17, 21]. 
 
α - lactose monohydrate has been reported as 
the most common present form in commercial batches. 
A study conducted on several samples revealed that at 
temperatures close to 177 ° C an endothermic event 
may occur due to the anomerization of α - lactose to β - 
lactose. In addition, it is mentioned that a small amount 
of water vapor is enough to cause such a physical 
change at temperatures higher than 150 °C, which is 
totally valid since it is difficult to think that all water 
within the crystal lattice has been removed in its first 
endotherm, taking into account that lactose has three 
[17].  
 
However, the mentioned event was not 
possible to confirm in our study since the thermograms 
didn’t show an endothermic peak at that temperature. 
Also, the melting point of β - lactose, which should be 
present at 234 °C, was not possible to appreciate either 
[17,22]. 
 
Nevertheless, the anomerization in the tablets 
can be overlapped with the crystallization exothermic 
event of the amorphous phase that is reported to occur 
at 172 °C. A way of confirming the crystallization is 
through the analysis of the respective TGA 
thermograms, which in our case didn’t show a mass 
loss, as should be expected since this is conceived as a 
physical change. Precisely, the third endotherm for 
lactose in the DSC analysis of placebos, powdered 
formulas and tablets, around 214 – 218 °C corresponds 
mostly to the melting of the stable α - lactose crystals 
which is reported to happen at 217 °C and it is followed 
by its decomposition [17]. 
 
The extra endotherm presented by the placebos 
helped to confirm the crystallization that the amorphous 
phase suffered due to compression, since the melting 
point of amorphous lactose is established to occur close 
to 223 °C and it is not presented in the tablets DSC 
thermograms [17]. 
 
X-ray diffraction is a very relevant technique 
that can be used to confirm the previously discussed 
results. Figures 5 and 6 show the classic peaks of α - 
lactose monohydrate in the placebos and the powdered 
formulas, specially its main peaks at 12.4, 16.4 and 19.8 
2θ. In the mentioned samples, it is quite difficult to 
identify the main peaks of β - lactose at 10.5 and 20.9 
2θ. This is probably due to an overlap with the 
crystalline signals of the other raw materials and to β – 
lactose’s relatively low presence [21].  
 
Even though the product of the crystallization 
is the stable form of α - lactose, the presence of water in 
the powdered samples led to its transformation into α - 
lactose monohydrate. Since the X-ray diffraction 
technique doesn’t eliminate water from the crystal 
lattice as DSC does, in the analysis of the tablets it is 
possible to observe α - lactose monohydrate’s peaks a 
bit more intense as a consequence of the crystallization 
of amorphous lactose induced by compression [22].  
 
Although amorphous lactose has been found to 
be more compressible than the crystalline forms, the 
change induced by compression doesn’t represent a 
disadvantage for the present formulations, since α - 
lactose monohydrate is still considered one of the most 
useful diluents because of its good flowability and 
consolidation by fragmentation. Also, it is important to 
remember that the selected batch for the development 
was mostly constituted by this crystalline form [8]. 
 
CONCLUSIONS  
Special attention should be paid for the 
evaluation of the manufacturing processes, specifically 
regarding the influence on the material attributes. The 
crystalline state of the raw materials for the 
development of pharmaceutical products is of great 
interest. Different crystalline forms can provide 
advantages in terms of formulation and the performance 
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of the pharmaceutical form, while other crystal 
arrangements may lead to poor dissolution, low 
bioavalability and therefore, a reduced therapeutic 
effect. 
 
The comparison between the analyses of the 
tablets and their corresponding placebos and powdered 
formulas that has been done in this investigation, 
confirmed that compression didn’t impact the 
crystalline state of the API, Rupatadine fumarate, since 
there’s only one possible crystal arrangement. However, 
the API’s fusion peak shifted towards lower 
temperatures clearly by the mechanical treatments and 
by the influence of the excipients. 
 
However, the analyses of the tablets suggest 
that lactose’s crystal lattice suffered the greatest impact 
caused by compression. The implemented 
manufacturing process generated the crystallization of 
the amorphous region present in that raw material, 
which was only possible to realize by the interpretation 
of the DSC thermograms, where an exothermic peak 
appeared around 172 – 176 °C without causing mass 
loss in the TGA. This was complemented by the 
increase in α - lactose monohydrate’s peak intensity, 
presented in the XRD diffractograms of the tablets. 
 
Although compression did influence the 
crystal lattice of one of the components of the matrix, 
such modification doesn’t alter the aptitude of the 
prototypes for being developed into a final solid 
pharmaceutical form, because it is not a modification 
that puts at risk the product’s quality. 
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